NCT00242827View on ClinicalTrials.gov

Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma

PHASE2TerminatedINTERVENTIONAL
Timeline

Start Date

April 30, 2006

Study Completion Date

May 31, 2007

Conditions
Myeloma
Interventions
DRUG

Oral CEP-701

Trial Locations (5)

10021

New York Presbyterian Hospital, New York

19104

Abramson Cancer Center Of University of Pennsylvania, Philadelphia

30302

Emory University Winship Cancer Institute, Atlanta

46202

Indiana Univeristy Cancer Research Center, Indianapolis

07601

The Cancer Center Hackensack University Medical Center, Hackensack

Sponsors

Lead Sponsor

Cephalon
All Listed Sponsors
lead

Cephalon

INDUSTRY

NCT00242827 - Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma | Biotech Hunter | Biotech Hunter